ACHV Stock Price, Achieve Life Sciences Quote, Chart

Market Summary

USD4.54+0.04

Market Closed

0.89%

ACHV Stock Price

View Fullscreen

ACHV RSI Chart

ACHV Valuation

Market Cap

154.1M

Price/Earnings (Trailing)

-5.17

Price/Sales (Trailing)

19.02

EV/EBITDA

-5.19

Price/Free Cashflow

-6.29

ACHV Price/Sales (Trailing)

ACHV Profitability

EBT Margin

-323.88%

Return on Equity

2.1K%

Return on Assets

-154.02%

Free Cashflow Yield

-15.9%

ACHV Fundamentals

ACHV Revenue

Revenue (TTM)

5.1M

ACHV Earnings

Earnings (TTM)

-29.8M

Earnings Growth (Yr)

51.07%

Earnings Growth (Qtr)

22.69%

Breaking Down ACHV Revenue

Last 7 days

2.7%

Last 30 days

-2.2%

Last 90 days

-1.1%

Trailing 12 Months

-44.3%

How does ACHV drawdown profile look like?

ACHV Financial Health

Current Ratio

0.82

Debt/Equity

-11.18

Debt/Cashflow

-1.51

ACHV Investor Care

Shares Dilution (1Y)

91.03%

Diluted EPS (TTM)

-1.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2016	19.7M	17.8M	11.1M	5.1M
2015	16.8M	15.9M	17.8M	18.2M
2014	36.5M	35.1M	30.1M	27.1M
2013	23.9M	27.8M	31.1M	29.9M
2012	5.6M	6.2M	11.6M	20.1M
2011	10.1M	10.3M	6.6M	5.5M
2010	0	21.6M	17.6M	13.6M
2009	0	0	0	25.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Achieve Life Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	jacobs cindy	acquired	-	-	16,250	president & cmo
Apr 19, 2024	jacobs cindy	sold (taxes)	-17,846	4.51	-3,957	president & cmo
Apr 19, 2024	wan jerry	acquired	-	-	5,625	principal accounting officer
Apr 19, 2024	wan jerry	sold (taxes)	-10,147	4.51	-2,250	principal accounting officer
Apr 19, 2024	stewart richard alistair	acquired	-	-	22,500	executive chairman
Apr 19, 2024	stewart richard alistair	sold (taxes)	-45,663	4.51	-10,125	executive chairman
Apr 19, 2024	bencich john	acquired	-	-	25,000	ceo
Apr 19, 2024	bencich john	sold (taxes)	-27,456	4.51	-6,088	ceo
Mar 04, 2024	stewart richard alistair	bought	45,850	4.585	10,000	executive chairman
Mar 04, 2024	bencich john	bought	45,850	4.585	10,000	ceo

Which funds bought or sold ACHV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	GODSEY & GIBB, INC	sold off	-100	-1,867	-	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	reduced	-1.92	52,259	690,154	-%
Apr 18, 2024	MANCHESTER FINANCIAL INC	unchanged	-	8,118	86,810	0.02%
Apr 17, 2024	Stephens Consulting, LLC	unchanged	-	1,275	13,635	-%
Apr 05, 2024	Madison Park Capital Advisors, LLC	unchanged	-	4,250	45,450	0.04%
Mar 11, 2024	VANGUARD GROUP INC	added	1.98	-58,473	2,495,520	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-101,502	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	sold off	-100	-29,184	-	-%
Feb 14, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	sold off	-100	-109,345	-	-%
Feb 14, 2024	LPL Financial LLC	added	8.51	28,070	735,420	-%

Are Funds Buying or Selling ACHV?

Are funds buying ACHV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACHV

No. of Funds

Unveiling Achieve Life Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	franklin resources inc	12.0%	4,365,755	SC 13G
Feb 27, 2024	callahan patrick j. iii	9.9%	2,167,439	SC 13G
Jun 02, 2023	contrarian alpha, lp	9.2%	1,978,377	SC 13G/A
Apr 18, 2023	dialectic capital management, lp	19.68%	3,538,093	SC 13G
Mar 23, 2023	dialectic capital management, lp	19.5%	3,494,000	SC 13D/A
Mar 06, 2023	dialectic capital management, lp	19.5%	3,494,000	SC 13D/A
Feb 13, 2023	francis capital management, llc	3.6%	648,648	SC 13G/A
Feb 10, 2023	svb financial group	8.8%	1,716,764	SC 13G/A
Jan 20, 2023	dialectic capital management, lp	19.5%	3,494,000	SC 13D
Nov 28, 2022	contrarian achieve spv, lp	369%	1,318,918	SC 13G

Recent SEC filings of Achieve Life Sciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Mar 28, 2024	10-K	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 11, 2024	SC 13G	Major Ownership Report
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading

Peers (Alternatives to Achieve Life Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Achieve Life Sciences Inc News

Latest updates

Achieve Life Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4	2012Q3	2012Q2	2012Q1	2011Q4
Revenue	-	-	-	2,122,000	2,940,000	6,024,000	6,737,000	4,025,000	1,374,000	5,653,000	4,803,000	4,929,000	11,731,000	8,604,000	9,862,000	6,340,000	5,076,000	9,780,000	6,570,000	2,429,000	1,316,000	1,236,000
Operating Expenses	-	-	-	-	7,372,000	9,503,000	11,428,000	-	6,371,000	-	12,045,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-20.4%	19.00	24.00	29.00	21.00	30.00	24.00	34.00	41.00	48.00	38.00	46.00	34.00	40.00	28.00	16.00	17.00	21.00	11.00	15.00	15.00	19.00
Current Assets	-22.4%	17.00	22.00	26.00	18.00	27.00	21.00	31.00	38.00	45.00	35.00	42.00	30.00	37.00	24.00	13.00	13.00	17.00	8.00	11.00	11.00	16.00
Cash Equivalents	-22.2%	16.00	20.00	25.00	17.00	25.00	18.00	29.00	36.00	43.00	33.00	42.00	30.00	36.00	22.00	12.00	12.00	17.00	7.00	10.00	7.00	10.00
Net PPE	-	0.00	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	2.6%	21.00	20.00	19.00	20.00	22.00	23.00	21.00	19.00	19.00	3.00	5.00	4.00	3.00	2.00	2.00	2.00	3.00	3.00	3.00	4.00	3.00
Current Liabilities	409.9%	21.00	4.00	3.00	20.00	22.00	7.00	5.00	4.00	5.00	3.00	5.00	4.00	3.00	2.00	2.00	2.00	3.00	3.00	3.00	4.00	3.00
Long Term Debt	-100.0%	-	16.00	16.00	-	-	16.00	15.00	15.00	15.00	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	17.00	-	-	16.00	16.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	16.00	16.00	-	-	16.00	15.00	15.00	15.00	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-135.9%	-1.45	4.00	10.00	0.00	8.00	1.00	13.00	21.00	28.00	35.00	41.00	30.00	37.00	26.00	15.00	15.00	18.00	8.00	12.00	10.00	16.00
Retained Earnings	-3.4%	-165	-160	-153	-144	-135	-124	-111	-101	-93.59	-86.43	-79.70	-68.43	-60.43	-55.71	-51.95	-49.02	-45.70	-42.51	-38.84	-31.29	-25.38
Additional Paid-In Capital	0.0%	164	164	163	145	144	126	125	123	122	121	121	98.00	98.00	81.00	66.00	64.00	64.00	51.00	50.00	41.00	41.00
Shares Outstanding	0%	21.00	21.00	21.00	18.00	18.00	10.00	10.00	9.00	8.00	8.00	7.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	91.00	-	-	-	47.00	-	-	-	85.00	-	-	-	15.00	-	-	-	15.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	14.1%	-4,379	-5,100	-6,700	-8,300	-11,143	-11,307	-8,340	-6,779	-5,218	-8,694	-9,076	-6,452	-2,480	-4,335	-2,198	-4,461	-3,414	-3,072	-3,841	-4,889	-3,541
Share Based Compensation	-100.8%	-9.50	1,174	1,189	1,085	778	829	840	823	494	530	621	542	395	281	308	302	284	310	317	290	266
Cashflow From Investing	-Infinity%	-6.00	-	-	-	-	-	-	-	-	-	-	-	-	-3.00	-12.00	-2.00	-1.00	-	2,347	2,690	-3,709
Cashflow From Financing	-	-	-	15,231	47.00	17,713	126	1,381	95.00	14,928	8.00	21,438	236	15,940	14,620	2,167	-47.00	12,703	-	-	-	5,010

ACHV Income Statement

2023-12-31

Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
EXPENSES
Research and development	$ 15,814	$ 30,078	$ 23,966
General and administrative	11,436	10,722	9,128
Total operating expenses	27,250	40,800	33,094
OTHER INCOME (EXPENSE)
Interest income	825	199	17
Interest expense [note 9]	(2,853)	(1,789)
Change in fair value of contingent consideration [note 6 and note 7]	(528)
Other income/(expense)	(9)	40	(75)
Total other income (expense)	(2,565)	(1,550)	(58)
Net loss and comprehensive loss	$ (29,815)	$ (42,350)	$ (33,152)
Basic net loss per common share [note 11 [i]]	$ (1.5)	$ (4)	$ (4.08)
Diluted net loss per common share [note 11 [i]]	$ (1.5)	$ (4)	$ (4.08)
Shares used in computation of basic net loss per common share [note 11 [i]]	19,827,354	10,593,034	8,119,836
Shares used in computation of Diluted net loss per common share [note 11 [i]]	19,827,354	10,593,034	8,119,836

ACHV Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents [note 3 and note 7]	$ 15,546	$ 24,771
Grant receivable [note 4]	111	105
Prepaid expenses and other assets	1,325	2,454
Total current assets	16,982	27,330
Restricted cash and other assets [note 7 and note 8]	92	66
Right-of-use assets [note 12]	66	123
License agreement [note 5 and note 6]	1,197	1,418
Goodwill	1,034	1,034
Total assets	19,371	29,971
Current liabilities:
Accounts payable	618	1,660
Accrued liabilities other	351	403
Contigent consideration [note 6 and note 7]	528
Accrued clinical liabilities	280	1,729
Accrued compensation	2,311	1,678
Current portion of long-term obligations [note 12]	63	58
Convertible debt [note 7 and note 9]	16,662	16,071
Total current liabilities	20,813	21,599
Long-term obligations [note 12]	6	69
Total liabilities	20,819	21,668
Commitments and contingencies [note 12]
Stockholders' equity:
Common stock, $0.001 par value, 150,000,000 shares authorized, 21,165,760 and 17,897,029 issued and outstanding at December 31, 2023 and December 31, 2022, respectively.	90	87
Additional paid-in capital	164,209	144,148
Accumulated deficit	(165,751)	(135,936)
Accumulated other comprehensive income	4	4
Total stockholders' equity	(1,448)	8,303
Total liabilities and stockholders' equity	19,371	29,971
Series A Convertible Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock, value

About Achieve Life Sciences Inc

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.

CEO	Mr. John A. Bencich M.B.A.
WEBSITE	achievelifesciences.com
INDUSTRY	Biotechnology
EMPLOYEES	20

Achieve Life Sciences Inc Frequently Asked Questions

What is the ticker symbol for Achieve Life Sciences Inc? What does ACHV stand for in stocks?

ACHV is the stock ticker symbol of Achieve Life Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Achieve Life Sciences Inc (ACHV)?

As of Tue Apr 23 2024, market cap of Achieve Life Sciences Inc is 154.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACHV stock?

You can check ACHV's fair value in chart for subscribers.

What is the fair value of ACHV stock?

You can check ACHV's fair value in chart for subscribers. The fair value of Achieve Life Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Achieve Life Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACHV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Achieve Life Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether ACHV is over valued or under valued. Whether Achieve Life Sciences Inc is cheap or expensive depends on the assumptions which impact Achieve Life Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACHV.

What is Achieve Life Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, ACHV's PE ratio (Price to Earnings) is -5.17 and Price to Sales (PS) ratio is 19.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACHV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Achieve Life Sciences Inc's stock?

In the past 10 years, Achieve Life Sciences Inc has provided -0.571 (multiply by 100 for percentage) rate of return.